Summary  
ECOG-ACRIN Cancer Research Group’s Marketing/Clinical Education and Awareness staff will use approved language/images to help increase awareness of EAQ222CD/CostCOM and support accrual efforts. The content below may be shared to the ECOG-ACRIN website, affiliated blogs, and social media channels. Links to these channels are included below. Staff at participating EAQ222CD/CostCOM sites may also use this content on their own institutions’ social media channels. This plan contains messaging tailored to patients and caregivers.

ECOG-ACRIN Website  
<https://www.ecog-acrin.org>

ECOG-ACRIN Blogs  
<https://blog-ecog-acrin.org>  
<https://advocacy-ecog-acrin.org>

Social Media Channels  
X/Twitter: <https://twitter.com/eaonc>  
Facebook: <https://www.facebook.com/eaonc/>   
LinkedIn: <https://www.linkedin.com/company/ecog-acrin-cancer-research-group/>  
Instagram: <https://www.instagram.com/ecog_acrin/>

Target Audience(s)  
Various cancer communities, including:

* Patients and survivors
* Caregivers
* Advocates
* Research, education, and advocacy organizations

Privacy/Confidentiality Considerations  
ECOG-ACRIN will make every possible effort to protect privacy and confidentiality by:

* Keeping social media post content general in nature and avoiding any specifics related to the trial or patients on the trial
* Refraining from direct engagement with individuals about their eligibility for trials
  + Instead, individuals will be directed to consult with their physician and/or the NCI’s Cancer Information Service
* Monitoring posts daily for inappropriate responses/interactions and flagging or removing as needed

General/Website Messaging

**EAQ222CD/CostCOM***Cost Communication and Financial Navigation in Cancer Patients*

**Why consider participating in this study?**

* Research studies are an important way to test the effectiveness of new approaches for supporting patients being treated for cancer.
* The usual approach for patients who are not in a study is to find out how much their cancer medication costs after undergoing treatment and receiving a bill. Furthermore, financial counseling is not routinely offered to all patients.
* In EAQ222CD/CostCOM, patients will get an estimate of how much they’ll have to pay before starting their treatment. In addition, financial counseling will be offered.
  + This study aims to find out if providing this level of support can make it easier for patients to stick to their treatment plan and lower the financial stress that comes with cancer treatment.

**What does this study involve?**

* If you decide to take part in this study, you will be assigned by chance (randomized) to one of two groups. Both groups will receive the usual care that is offered by the cancer clinic. You will have an equal chance of being in Group 1 or Group 2.
  + **Group 1:** You will receive a brochure with information about the Patient Advocate Foundation (PAF). PAF is a non-profit organization that offers free financial counseling. They also help patients sign up for financial assistance programs, if needed.
    - You can find the contact information for PAF in the brochure, and can ask for their services.
  + **Group 2:** You will have the opportunity to attend 4 free one-on-one financial navigation sessions with a financial counselor. These sessions are 1 hour each, and are set up by TailorMed Medical Inc., a company that provides price transparency and financial counseling.
    - During these sessions, the counselor will go over your health insurance details and give you an estimate of how much your medication will cost out-of-pocket. Financial counseling will also be offered, as well as assistance with signing up for financial aid programs, if needed.
    - The financial counseling sessions will occur when you first join the study, and at 3, 6, and 12 months after joining. You can choose to have these sessions over the phone or through video conference calls.
      * A close-up of a message

        Description automatically generatedYou will be asked to complete a 5-minute survey after each financial counseling session.
  + Participants in both groups will be asked to fill out surveys 4 times: at study enrollment, then 3, 6, and 12 months after joining EAQ222CD/CostCOM.
    - Each survey will take around 45 to 60 minutes and can be completed online or on paper. You do not have to answer any questions that make you uncomfortable.
  + The total time on study will be 12 months. However, you can decide to stop taking part in EAQ222CD/CostCOM at any time, even after you have enrolled.

**Who will take part in this study?**

* Approximately 720 people with any type or stage of solid cancer diagnosed within the past 120 days will take part in EAQ222CD/CostCOM. In order to participate in the study, you must:
  + Be 18 years of age or older, and speak English or Spanish
  + Have started/will be starting cancer medication within 30 days of joining the study
    - *Note:* Surgery or radiation therapy alone does not make you eligible for EAQ222CD/CostCOM. You must also be getting cancer medication in pill or IV form.

**What are the costs of taking part in this study?**

* There is no medical care or testing being given as part of EAQ222CD/CostCOM, and there are no expected costs to you for taking part in the study (including the financial counseling sessions, which are provided for free).
  + Participating in EAQ222CD/CostCOM shouldn’t change anything about how you normally receive treatment for your cancer. Please note that the cost of your treatment medication is not covered by the study.
* Participants will receive a gift card valued at $10 at completion of the first survey, $15 for the second survey (at 3 months), $20 for the third survey (at 6 months), and $25 for the fourth survey (at 12 months).

**If you would like to know more**

* About the EAQ222CD/CostCOM study, talk with your doctor, or:
  + Visit [www.ecog-acrin.org](http://www.ecog-acrin.org) and search EAQ222CD, then select the link to the EAQ222CD Home Page.
    - If you are seeking information about the locations where the study is available, scroll down the page to Locations and Contacts and click the + sign.
  + Call the NCI Cancer Information Service at 1-800-4-CANCER (1-800-422-6237).
* About clinical trials:
  + General cancer information: visit the NCI website at [www.cancer.gov](http://www.cancer.gov)
* About ECOG-ACRIN:
  + Visit [www.ecog-acrin.org](http://www.ecog-acrin.org)
  + For a list of patient resources and links to patient advocacy groups, visit <https://ecog-acrin.org/patients/resources>

Social Media Messaging

|  |  |
| --- | --- |
| **Facebook/LinkedIn** | **X/Twitter** |
| #ClinicalTrial EAQ222CD/CostCOM, led by Gelareh Sadigh, MD of @UCIrvineHealth, is testing the effectiveness of cost communication and financial navigation  in cancer patients. If you have any newly diagnosed solid cancer, you may be able to participate. https://bit.ly/EAQ222CD | #ClinicalTrial EAQ222CD/CostCOM, led by @GelarehSadigh, is testing the effectiveness of cost communication and financial navigation  in #CancerPatients. If you have any newly diagnosed #SolidCancer, you may be able to participate. https://bit.ly/EAQ222CD |
| Do you have cancer (any form of solid tumor) that has been recently diagnosed, and a new prescription for cancer medication? If so, you may be able to participate in this new research study, EAQ222CD/CostCOM. More info here: https://bit.ly/EAQ222CD | Do you have #Cancer (any form of #SolidTumor) that has been recently diagnosed, and a new prescription for cancer medication? If so, you may be able to participate in this new research study, EAQ222CD/CostCOM. More info here: https://bit.ly/EAQ222CD cc: @GelarehSadigh |
| Patients with newly diagnosed solid cancer may be eligible to participate in EAQ222CD/CostCOM. Learn more about this new research study here: https://bit.ly/EAQ222CD | Patients with newly diagnosed #SolidCancer may be eligible to participate in EAQ222CD/CostCOM. Learn more about this new research study here: <https://bit.ly/EAQ222CD> cc: @GelarehSadigh |

**Hashtags:** #SolidCancer, #CancerPatients, #Cancer

Images

****

A person and person looking at a computer

Description automatically generated****